Novartis (NVS) 2026 Earnings Outlook: Risks & Opportunities
Novartis faces a nuanced path in 2026, balancing new therapies with cost discipline. This guide breaks down the key d...
Pharmaceuticals
This tag page gathers 4 Pharmaceuticals articles covering stock moves, earnings previews, and dip-buys to help you evaluate pharma equities and manage risk.
35 articles
Ionis Pharmaceuticals Drops Another After Phase 3 Setback
Ionis Pharmaceuticals dropped again after a Phase 3 failure in transthyretin amyloid cardiomyopathy, triggering a bro...
Lilly Stock Climbed Record: Key Drivers Behind the New High
Eli Lilly shares surged to fresh highs, underpinned by upbeat analyst notes and strong pipeline momentum. This guide ...
PJP: Which Pharmaceutical Better? IHE vs PJP ETF Showdown
Choosing the right pharmaceutical ETF can shape your portfolio’s risk and income. This guide pits IHE against PJP, br...
Which Pharmaceutical Better, VanEck's PPH or Invesco's PJP?
Choosing the right pharmaceutical ETF can feel like balancing income with growth. This guide compares VanEck's PPH an...
Is Viking Therapeutics Stock Going to $100? Realistic Analysis
Investors are weighing big potential against real-world risk. This article breaks down VK2735, market dynamics, and w...
Reasons Lilly Better Stock: 5 Clear Advantages Over SpaceX
Investors face a choice between a pharmaceutical powerhouse with proven earnings and a high-growth space company unde...
Jazz Pharmaceuticals' Lung Cancer Setback: Stock Impact
A late-stage setback for Jazz Pharmaceuticals' lung cancer drug Zepzelca rattled investors, but the larger story may ...
Novo Nordisk's Wegovy Pill: Is Wall Street Missing Something Behind 3 Million Prescriptions?
A new milestone for obesity treatment arrives as Novo Nordisk's Wegovy Pill hits 3 million prescriptions. This articl...
Reasons Lilly Stock: 5 Key Upsides Investors Should Watch
This deep dive looks at why Lilly stock may be a standout pick for growth-focused investors. From a dominant obesity ...
IShares Pharma ETF vs SPDR's Biotech: Long-Term Buy?
Investors debating IHE vs XBI face a trade-off between stability and growth. This guide breaks down how ishares pharm...
AbbVie Stock Will $300: Timing and Risks to Watch
AbbVie’s Q1 2026 results show strong immunology growth even as biosimilar challenges weigh on revenue. Analysts debat...